RU2018117499A - Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов - Google Patents
Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов Download PDFInfo
- Publication number
- RU2018117499A RU2018117499A RU2018117499A RU2018117499A RU2018117499A RU 2018117499 A RU2018117499 A RU 2018117499A RU 2018117499 A RU2018117499 A RU 2018117499A RU 2018117499 A RU2018117499 A RU 2018117499A RU 2018117499 A RU2018117499 A RU 2018117499A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- independently selected
- alkyl
- Prior art date
Links
- WUQITSNWWRHLEP-UHFFFAOYSA-N 6-[5-amino-6-(2-ethoxyethoxy)imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile Chemical class NC1=C(C=C2C(=N1)N(C=N2)C1=NC=C(C#N)C=C1)OCCOCC WUQITSNWWRHLEP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- -1 2- {2- [3- (5-cyano-pyridin-2-yl) -5- (tetrahydropyran-4-ylamino) -3H-imidazo [4,5-b] pyridin-6-yloxy] ethoxy} - (S) -2-amino-3-methyl-butyric acid ethyl ester Chemical compound 0.000 claims 1
- VNAPWQDUDZCVCA-UHFFFAOYSA-N 6-[6-[2-(2-hydroxyethoxy)ethoxy]-5-(oxan-4-ylamino)imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile Chemical compound OCCOCCOC=1C=C2C(=NC=1NC1CCOCC1)N(C=N2)C1=NC=C(C#N)C=C1 VNAPWQDUDZCVCA-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518456.7 | 2015-10-19 | ||
| GBGB1518456.7A GB201518456D0 (en) | 2015-10-19 | 2015-10-19 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| PCT/EP2016/074662 WO2017067848A1 (en) | 2015-10-19 | 2016-10-14 | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018117499A true RU2018117499A (ru) | 2019-11-21 |
| RU2018117499A3 RU2018117499A3 (enExample) | 2020-01-24 |
Family
ID=55131239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018117499A RU2018117499A (ru) | 2015-10-19 | 2016-10-14 | Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10508111B2 (enExample) |
| EP (1) | EP3365341B1 (enExample) |
| JP (1) | JP2018530617A (enExample) |
| KR (1) | KR20180064528A (enExample) |
| CN (1) | CN108137584A (enExample) |
| AR (1) | AR106384A1 (enExample) |
| AU (1) | AU2016343225A1 (enExample) |
| BR (1) | BR112018007392A2 (enExample) |
| CA (1) | CA3002255A1 (enExample) |
| CO (1) | CO2018004765A2 (enExample) |
| GB (1) | GB201518456D0 (enExample) |
| IL (1) | IL258707A (enExample) |
| MX (1) | MX2018004517A (enExample) |
| PH (1) | PH12018500827A1 (enExample) |
| RU (1) | RU2018117499A (enExample) |
| SG (1) | SG11201803095UA (enExample) |
| TW (1) | TW201718582A (enExample) |
| WO (1) | WO2017067848A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| GB201702603D0 (en) * | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28506A1 (es) * | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
| GB2432834A (en) * | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| CA2825028A1 (en) * | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| RU2016110852A (ru) * | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
| UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
-
2015
- 2015-10-19 GB GBGB1518456.7A patent/GB201518456D0/en not_active Ceased
-
2016
- 2016-10-14 MX MX2018004517A patent/MX2018004517A/es unknown
- 2016-10-14 US US15/769,260 patent/US10508111B2/en not_active Expired - Fee Related
- 2016-10-14 BR BR112018007392A patent/BR112018007392A2/pt not_active Application Discontinuation
- 2016-10-14 AU AU2016343225A patent/AU2016343225A1/en not_active Abandoned
- 2016-10-14 CA CA3002255A patent/CA3002255A1/en not_active Abandoned
- 2016-10-14 SG SG11201803095UA patent/SG11201803095UA/en unknown
- 2016-10-14 JP JP2018538935A patent/JP2018530617A/ja not_active Ceased
- 2016-10-14 CN CN201680060910.6A patent/CN108137584A/zh active Pending
- 2016-10-14 WO PCT/EP2016/074662 patent/WO2017067848A1/en not_active Ceased
- 2016-10-14 RU RU2018117499A patent/RU2018117499A/ru not_active Application Discontinuation
- 2016-10-14 EP EP16794525.2A patent/EP3365341B1/en active Active
- 2016-10-14 KR KR1020187013738A patent/KR20180064528A/ko not_active Withdrawn
- 2016-10-17 AR ARP160103166A patent/AR106384A1/es unknown
- 2016-10-18 TW TW105133608A patent/TW201718582A/zh unknown
-
2018
- 2018-04-15 IL IL258707A patent/IL258707A/en unknown
- 2018-04-17 PH PH12018500827A patent/PH12018500827A1/en unknown
- 2018-05-03 CO CONC2018/0004765A patent/CO2018004765A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201518456D0 (en) | 2015-12-02 |
| US20180305351A1 (en) | 2018-10-25 |
| PH12018500827A1 (en) | 2018-10-29 |
| CO2018004765A2 (es) | 2018-07-19 |
| WO2017067848A1 (en) | 2017-04-27 |
| KR20180064528A (ko) | 2018-06-14 |
| IL258707A (en) | 2018-06-28 |
| JP2018530617A (ja) | 2018-10-18 |
| TW201718582A (zh) | 2017-06-01 |
| CN108137584A (zh) | 2018-06-08 |
| US10508111B2 (en) | 2019-12-17 |
| BR112018007392A2 (pt) | 2018-10-16 |
| RU2018117499A3 (enExample) | 2020-01-24 |
| AR106384A1 (es) | 2018-01-10 |
| EP3365341B1 (en) | 2020-05-13 |
| AU2016343225A1 (en) | 2018-05-10 |
| CA3002255A1 (en) | 2017-04-27 |
| SG11201803095UA (en) | 2018-05-30 |
| MX2018004517A (es) | 2018-06-27 |
| EP3365341A1 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018117499A (ru) | Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов | |
| JP2016515561A5 (enExample) | ||
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| BR112015023705A8 (pt) | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) | |
| SI3000813T1 (en) | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2016530259A5 (enExample) | ||
| EA201291348A1 (ru) | Активаторы растворимой гуанилатциклазы | |
| HRP20131021T1 (hr) | Novi 7-deazapurin nukleozidi za terapijske uporabe | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| BR112014032581A2 (pt) | inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune | |
| PH12019500804A1 (en) | Liposomal formulation for use in the treatment of cancer | |
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| RU2012135698A (ru) | Способ и композиция | |
| JP2013518036A5 (enExample) | ||
| EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| ECSP13012654A (es) | Composiciones farmacéuticas | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| EA201790179A1 (ru) | [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200730 |